#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Inborn error of metabolism Synovial sarcoma Encephalitis autoimmune Huntington's disease Glomerulonephritis Cholangitis sclerosing Hyperphagia Narcolepsy Niemann-Pick disease Extraskeletal ossification Subdural haematoma Superficial vein thrombosis Haemophagocytic lymphohistiocytosis Thymic carcinoma Anti-neutrophil cytoplasmic antibody positive vasculitis More trials…

    Learn about Rare Diseases

    Leiomyosarcoma – Trials in Disease Niemann-Pick disease – Basic Information Lennox-Gastaut syndrome – Diagnostics Cholangitis sclerosing – Trials in Disease Aicardi-Goutieres syndrome – Treatment Chondrosarcoma – Basic Information Pituitary-dependent Cushing’s syndrome – Trials in Disease Hypereosinophilic syndrome Angiosarcoma metastatic – Life with Disease Mitochondrial myopathy – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Xp-Dc+Tl+Klh A24110He Sotalol Hydrochloride Azd5462 Ly3473329 SECRETIN SYNTHETIC HUMAN Rp1 Cefotaxime Sodium Brinzolamide Crofelemer Zetomipzomib Cemiplimab Lithium Carbonate Prednisolone Acetate Lovotibeglogene Autotemcel Calcium Folinate Pentahydrate Folinic Acid Datopotamab Deruxtecan Nesolicaftor Patritumab Deruxtecan More therapies…

    Learn about Your Condition

    Retinal vein occlusion Oesophageal food impaction Mixed dementia Pulmonary sarcoidosis Neurodegenerative disorder Glioma Netherton's syndrome Pulmonary tuberculosis Choroid melanoma Sarcoma Hip arthroplasty Urethral stenosis Hyperglycaemia Pleomorphic liposarcoma Myxofibrosarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. ProLife Medica Sp. z O.O. ETG Poniatowa

ProLife Medica Sp. z O.O. ETG Poniatowa

Ul. Spadek 41, Poniatowa, 22-400, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Safety and Effectiveness of NEU-411 for Patients with Early Parkinson’s Disease

    Recruiting

    2 1
    Italy Poland Spain

  • Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn’s Disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Ro7790121
    Austria Belgium Bulgaria Croatia Czechia Denmark +10

  • Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn’s Disease After Inadequate Response to Other Treatments

    Recruiting

    2 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Obefazimod
    Belgium Czechia France Germany Hungary Italy +5

  • Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Humanised Igg4 Kappa Monoclonal Antibody Against Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl6, Cxcl7 And Cxcl8
    • Mirikizumab
    Belgium Croatia Czechia Denmark France Germany +8

  • Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiac failure
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Belgium Bulgaria Czechia Germany Hungary Italy +5

  • Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn’s Disease

    Recruiting

    2 1
    Investigated Drugs:
    • Zasocitinib
    Belgium Bulgaria Czechia Denmark France Germany +8

  • Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Rheumatoid arthritis
    Investigated Drugs:
    • Etanercept
    Bulgaria Hungary Poland Romania

  • Study on BI 3032950 for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Bi 3032950
    Belgium Czechia Poland Slovakia

  • A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Cardiovascular disorder
    Investigated Drugs:
    • Cagrilintide
    • Semaglutide
    Bulgaria Denmark France Germany Ireland Italy +3

  • A study testing tozorakimab for long-term treatment of chronic obstructive pulmonary disease in former smokers with repeated flare-ups

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Chronic obstructive pulmonary disease
    Investigated Drugs:
    • Salbutamol
    • Tozorakimab
    Belgium Bulgaria Czechia Denmark Finland France +11
1 2 3 4
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!